Acute coronary syndrome after liver transplantation in a young primary biliary cholangitis recipient with dyslipidemia: a case report

Siyuan Yao1,2*, Akiho Iwashita1, Shintaro Yagi3, Hirotoshi Watanabe4, Takahiro Nishio1, Yukinori Koyama1, Kazuyuki Nagai1, Naoko Kamo1, Kojiro Taura1 and Etsuro Hatano1

Abstract
Background: Primary biliary cholangitis (PBC) is a chronic, progressive liver disease associated with dyslipidemia. There is a consensus that PBC does not accelerate coronary artery disease despite high cholesterol levels, so the screening test for the coronary artery is not routinely performed before liver transplantation (LT). To date, no report has described the potential risk of PBC-related dyslipidemia for developing acute coronary syndrome (ACS) after LT.

Case presentation: A 40-year-old Asian female with a known history of PBC underwent ABO-incompatible living-donor LT, with her husband as the donor. Although she had high cholesterol and triglyceride levels that were refractory to medications, she passed all routine preoperative examinations, including cardiopulmonary function tests and infection screenings. One week after LT, she developed ACS with 90% stenosis of both the left anterior descending artery and left circumflex artery. Emergent stent implantation was successfully performed followed by dual antiplatelet therapy. The long history of PBC and associated severe dyslipidemia for 10 years would have accelerated the atherosclerosis, causing latent stenosis in the coronary artery. Inapparent stenosis might have become apparent due to unstable hemodynamics during the acute phase after LT.

Conclusions: PBC-related dyslipidemia potentially brings a risk for developing ACS after LT. This experience suggests that the preoperative evaluation of the coronary artery should be considered for high-risk patients, especially those who have drug-resistant dyslipidemia.

Keywords: Primary biliary cholangitis, Liver transplantation, Hypercholesterolemia, Hypertriglyceridemia, Coronary artery disease

Introduction
Primary biliary cholangitis (PBC) is a chronic, progressive liver disease associated with markedly elevated serum lipids. PBC is characterized by the loss of interlobular bile ducts due to degeneration and necrosis of bile duct epithelial cells, resulting in cholestasis and dyslipidemia. Since previous large observational studies failed to find an increased risk of serious coronary artery disease (CAD) in PBC patients, there is a consensus that PBC does not accelerate CAD despite high cholesterol levels [1, 2]. The practice guidelines for PBC do not cite the necessity of coronary artery investigation [3, 4]; thus, screening tests of the coronary artery are not routinely performed before liver transplantation (LT) at our department except for electrocardiogram and...
echocardiogram. Herein, we describe a young female patient with PBC-associated dyslipidemia who developed acute coronary syndrome (ACS) in the acute phase after living-donor liver transplantation (LDLT). This was the first case of ACS after LDLT among 1,980 recipients, including 125 with PBC, in the 30-year history of LT in our institution. The aim of this report is to demonstrate its unusual presentation and discuss the appropriate management strategy.

Case presentation
A 40-year-old Asian female with a known history of PBC underwent an ABO-incompatible LDLT (B to O), with her 31-year-old husband as the living donor. The patient was diagnosed with PBC at the age of 30 and was under treatment with ursodeoxycholic acid (UDCA) and pemafibrate for cholestasis and dyslipidemia. Despite treatment, her cholestasis worsened over time. The results of laboratory tests before LT are shown in Table 1. The Child–Pugh score, the Model for End-Stage Liver Disease score and the Mayo PBC risk score were 9, 12 and 9.98, respectively. She passed all routine preoperative examinations, including cardiopulmonary function tests (chest X-ray, spirometry, electrocardiogram, and echocardiography) and infection screenings. Despite the medication, she had a total cholesterol level of 343 mg/dL (normal range 140–219) and a triglyceride level of 307 mg/dL (normal range 38–149). Both high-density lipoprotein cholesterol and low-density lipoprotein (LDL) cholesterol were within the normal ranges. The chronological changes in these parameters and bilirubin are presented in Fig. 1. On physical examination, typical multiple palpebral and palmar xanthomas were observed. She had no other cardiovascular risk factors, such as smoking history, hypertension, diabetes mellitus, or family history of CAD. Her body mass index was 20.1 kg/m². Contrast-enhanced computed tomography (CT) did not show atherosclerotic plaques or calcifications in coronary arteries and abdominal vessels.

LDLT using a left-lobe graft was performed following rituximab induction and went without any serious intraoperative complications. Simultaneous splenectomy was performed for a low graft-to-spleen volume ratio based on our institutional strategy [5]. The operative time was 616 min, and blood loss was 1390 mL. Transfused red blood cells, fresh frozen plasma, and platelets were 560 mL, 240 mL, and 200 mL, respectively. The graft-to-recipient weight was 0.63%. The pathological findings of the original liver were compatible with PBC, and there was no evidence of malignancy.

The postoperative course was uneventful until POD 7, when hypotension emerged. She had never complained about chest pain before. Routine procedures, including cultures and contrast-enhanced CT, showed no evidence of infection. Since liver biopsy on POD 7 proved cellular rejection, steroid pulse therapy was immediately started. However, despite intense administration of catecholamine, the hypotension was refractory. On POD 9, poor contrast enhancement in the apex of the heart was noted by the radiologist’s review of the prior CT (Fig. 2A), and consequent electrocardiogram showed ST elevation in leads V1–4 (Fig. 2B). Troponin T and creatinine kinase MB (CK-MB) were elevated to 1.050 ng/mL (normal range ≤ 0.014) and 35 U/L (normal range ≤ 25), respectively. The patient was first referred to the cardiologist. As her echocardiogram showed akinesia of the apex and contrastive hypercontraction at the base, the diagnosis

**Table 1** Laboratory data before transplantation

| Pre-LT laboratory data | Creatinine 0.61 mg/dL | eGFR 85.4 mL/min/1.73 m² |
|------------------------|-----------------------|--------------------------|
| WBC 5600 /μL | | |
| Hemoglobin 8.5 g/dL | Total cholesterol 343 mg/dL |
| Platelet 17.7 x 10^5/μL | Triglyceride 307 mg/dL |
| INR 1.12 | HLD 87 mg/dL |
| AST 169 U/L | LDL 85 mg/dL |
| ALT 55 U/L | Ammonia 49 μg/dL |
| ALP 1772 U/L | CRP 6.9 mg/dL |
| γ-GTP 397 U/L | Child–Pugh score 9 |
| Albumin 2.6 g/dL | MELD score 12 |
| Total bilirubin 12.5 mg/dL | Mayo risk score 9.98 |
| Direct bilirubin 8.7 mg/dL | |

**Fig. 1** Chronological changes in parameters. LDLT living donor liver transplantation, T-CHOL total cholesterol, TG triglycerides, HDL high-density lipoprotein, LDL low-density lipoprotein, T-BIL total bilirubin
of Takotsubo cardiomyopathy was made. Although conservative treatment by fluid loading and vasopressor administration was continued, the response was poor, and symptoms such as nausea and chest pain appeared. On POD 13, coronary CT angiography (CCTA) was performed for further evaluation, and stenoses of the left anterior descending artery (Fig. 2C) and the left circumflex artery (Fig. 2D) were suspected. Troponin T was elevated to 2.750 ng/mL, and CK-MB was 33 U/L. The diagnosis of ACS was made, and emergent percutaneous coronary intervention was performed on POD 13. Emergent coronary angiography demonstrated 90% stenosis of both the left anterior descending artery (#6–7) and the left circumflex artery (#14) (Fig. 3A, B). Two drug-eluting stents (DESs) in the left anterior descending artery and one DES in the left circumflex artery were implanted (Fig. 3C, D). Dual antiplatelet therapy with aspirin and prasugrel hydrochloride was subsequently started.

After the above interventions, her blood pressure recovered, and all the symptoms disappeared. No further elevation of cardiac enzymes, including troponin T and CK-MB, was observed. These values gradually normalized over the course of a month (0.056 ng/mL for troponin T and <5 U/L for CK-MB on POD 35). The patient was discharged home on POD 46 after treatment for cellular rejection. Serum lipids immediately returned

**Fig. 2** Cardiovascular evaluation. A Poor contrast enhancement in the apex (white arrow) on CT on POD 7. B ST elevation in leads V1–4 on the electrocardiogram on POD 9. C Suspicious stenosis in the left anterior descending artery on coronary CT angiography on POD 13 (white arrow). D Suspicious stenosis in the left circumflex artery on coronary CT angiography on POD 13 (white arrow). AV AV node artery, CT computed tomography, LAD left anterior descending artery, LCX left circumflex artery, PD poster descending branch, POD postoperative day
to normal levels (Fig. 1), and the xanthomas had almost disappeared at the 6-month follow-up (Fig. 4). The graft function was good at the 18-month follow-up.

Discussion
To the best of our knowledge, no previous report has described the potential risk that PBC-related dyslipidemia will lead to ACS after LT.

PBC is closely related to dyslipidemia due to cholestasis, and 75–95% of the patients with PBC have dyslipidemia [6]. Cholestasis reduces bile acid secretion, leading to diminished bile acid synthesis and down-regulation of hepatic cholesterol synthesis. The effectiveness of combination therapy using UDCA and fibrate in improving biliary enzymes and the Mayo Risk Score has been confirmed in retrospective and prospective studies [7–10], and it is the standard treatment today. On the other hand, although dyslipidemia is a common finding in PBC, the risk of cardiovascular events in PBC patients is not higher than that of the general population. The cumulative incidences of ACS in the Asian PBC population are not high [11]. A similar incidence between PBC and normal populations has also been reported in Western countries [2, 12]. These findings suggest that cholesterol metabolism in PBC is different from that in the normal population. Previous studies demonstrated that low lecithin-cholesterol acyltransferase (LCAT) levels and high concentrations of lipoprotein-X and adiponectin concentrations play protective roles against atherogenesis in PBC [12–16]. Particularly, decreased LCAT function leads to changes in lipoprotein composition, decreased LDL and increased lipoprotein-X [15, 16]. Lipoprotein-X prevents LDL oxidation, thus protecting endothelial cells and slowing atherosclerosis [17, 18]. Adiponectin, which is considered to be associated with protection against atherosclerosis, is also increased in patients with PBC compared with controls [14].
While cohort studies are rare regarding this topic, an LT center in the United States reported that the incidence of ACS (including unstable angina and myocardial infarction) after LT was 5.4% among 389 recipients [19]. In addition to traditional coronary risk factors (e.g., hypertension, dyslipidemia), diabetes mellitus, age, pretransplant requirement for vasopressors, and specific pathology, such as nonalcoholic steatohepatitis, are known to increase the risks [19, 20]. In the present patient, we did not see her dyslipidemia as a major problem because she was a young adult without any other risks, and her electrocardiogram and echocardiogram before surgery were normal. However, the refractory dyslipidemia surely did harm. As a reference, the median values of serum total cholesterol and triglyceride before LT in all 125 PBC recipients at Kyoto University were 110 mg/dL (range 25–793) and 100 mg/dL (range 20–469), respectively. She had the 8th highest total cholesterol and 2nd highest triglyceride levels before LT at this institution. Moreover, her peak value of total cholesterol 1 year prior to LDLT was 1287 mg/dL. The long history of PBC and associated severe dyslipidemia for 10 years would have accelerated her atherosclerosis, causing latent stenosis in the coronary artery. Consequently, this inapparent stenosis might have become apparent due to the unstable hemodynamics during the acute phase after LDLT.

Hemoconcentration caused by the post-LT dehydration or hypovolemia might potentially contribute to the pathogenesis of ACS as well as atherosclerosis. In the present case, the platelet count reached a peak with $74.9 \times 10^4/\mu L$ on POD 5. Generally, the platelet counts in LDLT recipients with splenectomy normally reach a nadir at POD 5, but returns to preoperative levels by day 14, then reaches a peak and levels off after one month [5]. Considering that her pre-LT platelet count was $17.7 \times 10^4/\mu L$, the value on POD 5 was extremely high. Chronological change in platelet counts is shown in Fig. 5. Although we did not recognize, hemoconcentration could have existed early after LT. The increased urea nitrogen (36 mg/dL) and creatinine levels (0.83 mg/dL) and decreased estimated glomerular filtration rate (60.2 mL/min/1.73m²) on POD 5 would support our speculation. The association between ACS and essential thrombocythemia has been previously described [21, 22]. Although the increase in the present case was transient, its potential negative influence cannot be denied.

ABO incompatibility and rejection are also well-known risk factors for morbidity after LT [23–25]. However, based on our analyses, no one experienced ACS among 84 ABO-incompatible LTs and 142 recipients with post-LT rejection from 2006 to 2017 [5].
While it has not been studied in the field of LT, a previous report in the field of renal transplantation found no clear association between allograft rejection and ACS among 14,237 patients [26]. Therefore, these two factors seem less relevant to the pathogenesis of ACS.

Although we acknowledge that this is a very rare complication, early postoperative CAD could easily lead to serious morbidity and mortality; thus, the preoperative evaluation of the coronary artery should be considered for selected patients. In particular, a patient with a long history of PBC and drug-resistant dyslipidemia would be a suitable candidate. According to a recent report, the selective use of dobutamine stress echocardiography, CCTA and coronary angiography would be a safe and feasible approach in LT recipients [27]. However, considering the medical cost and burden, widespread evaluation in low-risk patients is not realistic. Through this experience, at Kyoto University, a PBC patient will be referred to a cardiologist when xanthomas, drug-resistant dyslipidemia, or other cardiovascular risk factors (smoking, arterial hypertension, obesity, and diabetes mellitus) exist regardless of age. At the same time, more careful attention to perioperative fluid management is demanded in these patients.

In conclusion, we want to raise the question of whether screening for coronary arteries in PBC patients with dyslipidemia is needed. In a highly invasive procedure such as organ transplantation where failure is unacceptable, a higher level of preoperative screening would be demanded even in young patients if their risk is high.

Abbreviations
ACS: Acute coronary syndrome; CAD: Coronary artery disease; CCTA: Coronary CT angiography; CK-MB: Creatinine kinase MB; CT: Computed tomography; DES: Drug-eluting stent; LDL: Low-density lipoprotein; LDLT: Living donor liver transplantation; LT: Liver transplantation; PBC: Primary biliary cholangitis; UDCA: Ursodeoxycholic acid.

Acknowledgements
The authors are grateful to the members of the Transplantation Counseling Office in Kyoto University for arranging all liver transplantations.

Author contributions
SY and AI are responsible for the acquisition, analysis, and interpretation of the data and the drafting of the manuscript. HW revised the manuscript from the standpoint of a cardiologist. SY, TN, NK, KN, NK, and KT performed the operations. EH was responsible for the revision of the manuscript for important intellectual content. All authors issued final approval for the version to be submitted. All authors read and approved the final manuscript.

Funding
This research received no specific Grant from any funding agencies.

Availability of data and materials
The data that support the findings of this study are available from the corresponding author upon reasonable request.

Declarations
Consent for publication
Informed written consent was obtained from the patient for publication of this case report and accompanying images.

Competing interests
The authors declare no conflicts of interest for this article.

Author details
1Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan. 2Department of Surgery, Kobe City Medical Center West Hospital, Hyogo, Japan. 3Department of Surgery, Graduate School of Medicine, Kanazawa University, Ishikawa, Japan. 4Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Received: 20 April 2022 Accepted: 10 June 2022
Published online: 17 June 2022

References
1. Longo M, Crosignani A, Battezzati PM, Squarcia Giussani C, Invernizzi P, Zuin M, et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut. 2002;51:265–9.
2. Sorokin A, Brown JL, Thompson PD. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review. Atherosclerosis. 2007;194:293–9.
3. Lindor KD, Bovlus CL, Boyer J, Levy C, Mayo M. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69:394–419.
4. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51:237–67.
5. Yao S, Kaido T, Yagi S, Uozumi R, Iwamura S, Miyachi Y, et al. Impact of imbalanced graft-to-spleen volume ratio on outcomes following living donor liver transplantation in an era when simultaneous splenectomy is not typically indicated. Am J Transplant. 2019;19:2783–94.
6. Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis. Lancet. 2015;386:1565–75.
7. Iwasaki S, Ohira H, Nishiguchi S, Zeniya M, Kaneko S, Onji M, et al. The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study. Hepatol Res. 2008;38:555–64.
8. Hosonuma K, Sato K, Yamazaki Y, Yanagisawa M, Hashizume H, Horiguchi N, et al. A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia. Am J Gastroenterol. 2015;110:423–31.
9. Tanaka A, Hirohara J, Naokuma Y, Tsunouchi H, Takikawa H. Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA. J Gastroenterol. 2015;50:675–82.
10. Yamaguchi M, Asano T, Aisaka T, Mashima H, Iwasawa A, Tamano M. Effects of pemafibrate on primary biliary cholangitis with dyslipidemia. Hepatol Res. 2022. Online ahead of print.
11. Lin CY, Cheng YT, Chang ML, Chien RN. The extrahepatic events of Asian patients with primary biliary cholangitis: a 30-year cohort study. Sci Rep. 2019;9:7577.
12. Crippin JS, Lindor KD, Jorgensen R, Kottke BA, Harrison JM, Murtaugh PA, et al. Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk? Hepatology. 1992;15:858–62.
13. Gylling H, Färkkilä M, Vuorio M, Miettinen TA. Metabolism of cholesterol and low- and high-density lipoproteins in primary biliary cirrhosis: cholesterol absorption and synthesis related to lipoprotein levels and their kinetics. Hepatology. 1995;21:89–95.
14. Floreani A, Viali A, Niro G, Premoli A, Baldo V, Gambino R, et al. Plasma adiponectin levels in primary biliary cirrhosis: a novel perspective for link between hypercholesterolemia and protection against atherosclerosis. Am J Gastroenterol. 2008;103:1959–65.

Received: 20 April 2022 Accepted: 10 June 2022
Published online: 17 June 2022

Declarations
Consent for publication
Informed written consent was obtained from the patient for publication of this case report and accompanying images.

Competing interests
The authors declare no conflicts of interest for this article.

Author details
1Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan. 2Department of Surgery, Kobe City Medical Center West Hospital, Hyogo, Japan. 3Department of Surgery, Graduate School of Medicine, Kanazawa University, Ishikawa, Japan. 4Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
15. Kunnen S, Van Eck M. Lecithin: cholesterol acyltransferase: old friend or foe in atherosclerosis? J Lipid Res. 2012;53:1783–99.
16. Fellin R, Manzato E. Lipoprotein-X fifty years after its original discovery. Nutr Metab Cardiovasc Dis. 2019;29:4–8.
17. Chang PY, Lu SC, Su TC, Chou SF, Huang WH, Morrisett JD, et al. Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation. J Lipid Res. 2004;45:2116–22.
18. Su TC, Hwang JJ, Kao JH. Hypercholesterolemia in primary biliary cirrhosis. N Engl J Med. 2007;357:1561–2.
19. Nicolau-Raduci R, Gitman M, Gani D, Loss GE, Cohen AJ, Patel H, et al. Adverse cardiac events after orthotopic liver transplantation: a cross-sectional study in 389 consecutive patients. Liver Transpl. 2015;21:13–21.
20. VanWagner LB, Harinstein ME, Runo JR, Darling C, Serper M, Hall S, et al. Multidisciplinary approach to cardiac and pulmonary vascular disease risk assessment in liver transplantation: an evaluation of the evidence and consensus recommendations. Am J Transplant. 2018;18:30–42.
21. Kumagai N, Mitsutake R, Miura S, Kawamura A, Takamiya Y, Nishikawa H, et al. Acute coronary syndrome associated with essential thrombocythemia. J Cardiol. 2009;54:485–9.
22. Xiong N, Gao W, Pan J, Luo X, Shi H, Li J. Essential thrombocythemia presenting as acute coronary syndrome: case reports and literature review. J Thromb Thrombolysis. 2017;44:57–62.
23. Adams DH, Sanchez-Fueyo A, Samuel D. From immunosuppression to tolerance. J Hepatol. 2015;62:S170–85.
24. Kubota T, Hata K, Sozu T, Ueda Y, Hirao H, Okamura Y, et al. Impact of donor age on recipient survival in adult-to-adult living-donor liver transplantation. Ann Surg. 2018;267:1126–33.
25. Jadlowiec CC, Morgan PE, Nehra AK, Hathcock MA, Kremers WK, Heimbach JK, et al. Not all cellular rejections are the same: differences in early and late hepatic allograft rejection. Liver Transpl. 2019;25:425–35.
26. Abbott KC, Bucci JR, Cruess D, Taylor AJ, Agodoa LY. Graft loss and acute coronary syndromes after renal transplantation in the United States. J Am Soc Nephrol. 2002;13:2560–9.
27. Robertson M, Chung W, Liu D, Seagar R, D’Halloran T, Koshy AN, et al. Cardiac risk stratification in liver transplantation: results of a tiered assessment protocol based on traditional cardiovascular risk factors. Liver Transpl. 2021;27:1007–18.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.